Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FKEKU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $46,422
Award facts
- Contract value 100% obligated
- $46,422.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $46,422 to DMS Pharmaceutical Group Inc. on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, specializing in distributing branded and generic prescription drugs, biologics, and medical consumables to federal healthcare facilities. The delivery order utilizes firm fixed-price pricing with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a comprehensive $500 million vehicle valid through November 2026 that enables the agency to procure a broad spectrum of pharmaceutical products supporting military health facility needs.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its existing IDC with DLA, which facilitates ongoing delivery orders for prescription medications, vaccines, specialty pharmaceuticals, and medical supplies to Department of Defense healthcare sites nationwide. The company's robust portfolio of previous contract awards demonstrates its capability to supply complex pharmaceutical products including oncology treatments, auto-injectors, biologics, and other specialized medications. This particular delivery order for Xolair, an immunosuppressant biologic medication, exemplifies the vendor's continued role in supporting military healthcare operations through reliable pharmaceutical distribution and logistics services.
Quick answers
Who was awarded contract SPE2DB25FKEKU?
SPE2DB25FKEKU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 27, 2025.
How much is contract SPE2DB25FKEKU worth?
The government has obligated $46,422 on SPE2DB25FKEKU.
Is contract SPE2DB25FKEKU an order under another contract?
Yes. SPE2DB25FKEKU is a delivery order under SPE2DB24D9223, an indefinite delivery contract.
Was contract SPE2DB25FKEKU competed?
The extent of competition for SPE2DB25FKEKU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award